I assumed, perhaps naively, that if a licensed pharmacy was producing a medication, there would be evidence behind it

Creator Pratley R.E Other Affiliation: AdventHealth Translational Research Institute, Orlando, FL, United States Crowley M.J Other Affiliation: Department of Medicine, Division of Endocrinology, Duke University Medical Center, and Durham Center of Innovation to Accelerate Discovery and Practice Transformation (ADAPT), Durham, NC, United States Gislum M Other Affiliation: Novo Nordisk A/S, Sborg, Denmark Hertz C.L Other Affiliation: Novo Nordisk A/S, Sborg, Denmark Jensen T.B Other Affiliation: Novo Nordisk A/S, Sborg, Denmark Khunti K Other Affiliation: Diabetes Research Centre, University of Leicester, Leicester, United Kingdom Mosenzon O Other Affiliation: Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel Buse J.B School of Medicine, Department of Medicine Abstract Introduction: The efficacy and safety of oral semaglutide, the first oral glucagon-like peptide-1 receptor agonist, were investigated in patients with type 2 diabetes (T2D) in the Peptide InnOvatioN for Early diabEtes tReatment (PIONEER) programme

A clinical review noted that hypocalcemia could lead to paresthesia (tingling) in extremities due to altered nerve function
Recalls & Warnings October 22, 2019 Seller of TrueAloe and AloeCran Settles Charges of Making False Claims NatureCity, LLC, has agreed to settle Federal Trade Commission (FTC) charges that they deceived consumers by making false claims about their TrueAloe and AloeCran products